The Guardian
‘Covid live: Egypt starts vaccine trial; Austria to put unvaccinated people in lockdown‘
In the News
Please find below a selection of recent media coverage in which the Gylden Pharma story is featured.
Applied Clinical Trials
‘NIH Selects T Cell-Priming Vaccine Candidate to be Included in Clinical Trials Under Project NextGen‘
October 7, 2024
Clinical Trials Arena
‘NIH selects Emergex’s T cell vaccine for trials under Project NextGen‘
October 3, 2024
*Article published before company name change from Emergex Vaccines Holding Limited to Gylden Pharma Limited.
Pharmaceutical Executive
‘Preparing for Outbreaks: Q&A with Thomas Rademacher, MD, PhD‘
June 26, 2024
Pharmaceutical Executive
‘Discovering the Need for Vaccines Against RNA Viruses: Q&A with Thomas Rademacher, MD, PhD‘
June 20, 2024
Citeline SCRIP
‘Emergex Goes to Battle Against ‘The Nasties’‘
May 3, 2024
*Interview conducted before company name change from Emergex Vaccines Holding Limited to Gylden Pharma Limited.
Genetic Engineering and Biotechnology News (GEN)
‘Vaccine Developers Leverage mRNA and Other Powerful Technologies’
May 1, 2024
Progress, Potential, and Possibilities Podcast
Prof. Thomas Rademacher, MD, PhD – CEO and Co-Founder, Emergex – T Cell-Priming Immunotherapies
April 17, 2024
*Interview conducted before company name change from Emergex Vaccines Holding Limited to Gylden Pharma Limited.
Life Science Success Podcast
Professor Thomas Rademacher, MD, PhD – CEO Emergex
February 3, 2024
*Interview conducted before company name change from Emergex Vaccines Holding Limited to Gylden Pharma Limited.
Outsourced Pharma
4-part editorial series
Part 1: ‘Vaccine Manufacture From the UK to Brazil and Saudi Arabia‘ – January 22, 2024
Part 2: ‘Creating T Cell Vaccines In the Sands‘ – January 25, 2024
Part 3: ‘Beyond (And Better Than) mRNA: T Cell Vaccines‘ – February 1, 2024
Part 4: ‘Creative Outsourcing Strategies, But Fill-Finish Still a Concern‘ – February 5, 2024
Infection Control Today
3-part publication
Part 1: ‘Chikungunya: What is it, Why is it Dangerous, and What is Being Done to Help?‘ – December 18, 2023
Part 2: ‘Discussing Chikungunya Current and Future Chikungunya Vaccines‘ – January 5, 2024
Part 3: ‘A Breakthrough Approach to Chikungunya Prevention: Understanding T Cell Vaccines‘ – January 10, 2024
BioProcess International
‘Emergex inks deal with VIC to bolster Saudi Arabia healthcare accessibility’
October 18, 2023
*Article published before company name change from Emergex Vaccines Holding Limited to Gylden Pharma Limited.
BioSpectrum Asia
‘Saudi Arabia’s Vaccine Industrial Company advances novel infectious disease solutions’
October 10, 2023
Pharmaceutical Technology
‘Emergex and VIC to develop infectious disease therapies in the Gulf’
October 6, 2023
*Article published before company name change from Emergex Vaccines Holding Limited to Gylden Pharma Limited.
Citeline SCRIP
‘Emergex CEO Questions mRNA Vaccines Against ‘Wuhan Virus,’ Works on Universal Vaccines’
August 31, 2023
*Article published before company name change from Emergex Vaccines Holding Limited to Gylden Pharma Limited.
Infection Control Today
‘Dengue Fever and Betacoronavirus: T cell-priming Immune Set-Point Candidates‘
July 12, 2023
European Pharmaceutical Review
‘Anatomy of a ‘correlate of protection’ for T-cell vaccines‘
June 16, 2022
NanoPass Technologies Ltd
January 26, 2022
*Article published before company name change from Emergex Vaccines Holding Limited to Gylden Pharma Limited.
The Guardian
December 11, 2021
The Guardian
‘UK firm to trial T-cell Covid vaccine that could give longer immunity‘
November 15, 2021
November 14, 2021
CNBC News interview with Emergex CEO, Professor Thomas Rademacher
May 14, 2018
*Interview conducted before company name change from Emergex Vaccines Holding Limited to Gylden Pharma Limited.
